CytomX TherapeuticsCTMX
CTMX
About: CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Employees: 121
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
3.17% less ownership
Funds ownership: 59.69% [Q4 2024] → 56.52% (-3.17%) [Q1 2025]
6% less funds holding
Funds holding: 70 [Q4 2024] → 66 (-4) [Q1 2025]
23% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 26
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
40% less capital invested
Capital invested by funds: $48.1M [Q4 2024] → $28.8M (-$19.3M) [Q1 2025]
70% less call options, than puts
Call options by funds: $9K | Put options by funds: $30K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
82%
upside
Avg. target
$5
82%
upside
High target
$5
82%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor | 82%upside $5 | Buy Reiterated | 20 May 2025 |
Piper Sandler Joseph Catanzaro | 82%upside $5 | Overweight Maintained | 15 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET.
Neutral
GlobeNewsWire
3 weeks ago
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma.
Positive
Seeking Alpha
1 month ago
CytomX Therapeutics: Doubling Overnight On Phase 1 Data
CytomX Therapeutics' CX-2501 shows promising phase 1 results in refractory colorectal cancer, with a 27.8% objective response rate and manageable toxicity. CTMX's financial position strengthened by a $100 million stock offering, extending cash runway through 2025. CX-904 development with Amgen discontinued, but collaboration continues on a preclinical T-cell engager project.
Neutral
Seeking Alpha
1 month ago
CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden - CFO Wayne Chu - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Anupam Rama - JPMorgan Peter Lawson - Barclays Robert Driscoll - Wedbush Securities Daniel Smith - H.C. Wainwright Operator Good morning, everyone, and thank you for standing by.
Positive
Benzinga
1 month ago
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report
CytomX Therapeutics, Inc.‘s CTMX share price was up 94.46% at last check on Monday.
Positive
Zacks Investment Research
1 month ago
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.17 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on May 13, 2025, subject to customary closing conditions.
Neutral
GlobeNewsWire
1 month ago
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) -
Neutral
GlobeNewsWire
1 month ago
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion ( 7.2, 8.6 and 10 mg/kg Q3W) -
Neutral
GlobeNewsWire
1 month ago
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May 12, 2025, before the open of the U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT.
Charts implemented using Lightweight Charts™